Guillermo Mazzolini
Guillermo Mazzolini is an expert in Hepatology at Universidad Austral de Chile (Chile). As of October 2026, ScienceLeadR ranks Guillermo Mazzolini in the top 1% of experts in Chile for Liver Neoplasms and Carcinoma. Guillermo Mazzolini has authored 152 publications, the most recent in 2026. SLR score: 542 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 152
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma. PMID 42306568 — cells, catenins, carcinoma, hepatocellular, neoplasms, immunotherapy, histones, immunosuppression therapy, tumor microenvironment | Mol Ther Oncol | 2026 | 1 |
| Context matters for SMYD2 in liver disease: from hepatoprotection to tumour immune escape. PMID 42236224 — liver diseases, liver | Gut | 2026 | 0 |
| IMT504 accelerates post-hepatectomy liver regeneration in mice with involvement of GLAST + Wnt1 + bone marrow stromal progenitors. PMID 41174046 — liver regeneration, cells, hepatocytes, bone marrow, liver, hepatectomy, natural science disciplines | Sci Rep | 2025 | 0 |
| RAC1 as a novel therapeutic target for acute liver failure. PMID 41098236 — cells, genes, hepatocytes, stress, physiological, oxidative stress, liver, liver failure, acute, therapeutics, liver failure | JHEP Rep | 2025 | 0 |
| Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications. PMID 40987534 — carcinoma, hepatocellular, gastroenterology, therapeutics | Gut | 2025 | 2 |
LeadR Networks
Main global connection map